Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

BACKGROUND: Docetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for Health and Clinical Excellence (NICE) preli...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Lixian, Pon, Vickie, Srinivas, Sandy, Nguyen, Nicole, Frear, Meghan, Kwon, Sherry, Gong, Cynthia, Malmstrom, Robert, Wilson, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661482/
https://www.ncbi.nlm.nih.gov/pubmed/23717582
http://dx.doi.org/10.1371/journal.pone.0064275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661482/
https://www.ncbi.nlm.nih.gov/pubmed/23717582
http://dx.doi.org/10.1371/journal.pone.0064275

Ejemplares similares